At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”. In all, it has added nine new active substances for the generics market by investing across several lines and at multiple facilities in its network.
In partnership with Aguettant Pharmarmaceutical, Italy’s Olon Group is to expand and renovate its plant in Mulazzano, which is dedicated to the production by enzymatic transformation. It will install reactors, filters and ancillary equipment, as well as automating and digitalising some steps performed there.
During its 2020 results presentation, Italian API producer Olon announced the completion of a large-scale, multi-purpose, high-containment HPAPI production line at its Rodano site near Milan. This is already available to customers, the firm added.